Matrix metalloproteinase inhibitor

Matrix metalloproteinase inhibitor" refers not to a single molecule or receptor, but to a class of compounds that inhibit the enzymatic activity of matrix metalloproteinases (MMPs), which are zinc-dependent endopeptidases responsible for the degradation of extracellular matrix components[1][3][5][6][8]. MMP inhibitors are explored primarily as therapeutic agents in cancer, where MMPs facilitate tumor invasion, metastasis, and angiogenesis, as well as in inflammatory and degenerative diseases[1][3][6][7]. Several synthetic (e.g., marimastat, batimastat, doxycycline) and biological (e.g., tissue inhibitors of metalloproteinases, TIMPs) inhibitors have been developed, though drug development is complicated by issues of specificity, efficacy, and side effects—most notably, musculoskeletal syndrome and impaired healing[3][4][6]. Thus, "matrix metalloproteinase inhibitor" is a pharmacological class, not a unique therapeutic target. For use in structured databases focused on targets rather than drug classes, this entry is considered incorrect and should be replaced with specific MMP enzyme names (e.g., Matrix metalloproteinase-9, abbreviation MMP-9) for precise target information[3][6].

Other names

MMP inhibitormetalloprotease inhibitor

Inhibition of matrix metalloproteinase (MMP) enzyme activity via chelation of the enzymatic zinc ion. Occupation of the active site of MMPs. Disruption of MMP interaction with substrates or cell surface partners.